Encinitas, California — February 19, 2026 — Leads & Copy — Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 3:20 p.m. ET.
A live webcast will be available on Kiora’s investor relations website, ir.kiorapharma.com, on the IR homepage and under the News & Events section. A replay of the webcast will be available for approximately 90 days.
Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on creating advanced therapies for retinal disease. The company targets critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss.
Kiora’s lead product candidates include:
KIO-104: Being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
KIO-301: Being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration.
Kiora Pharmaceuticals expects to post information relevant to investors on its website, www.kiorapharma.com, and social media accounts. The company encourages investors to follow them on X and LinkedIn and to visit their website and/or subscribe to email alerts.
Source: Kiora Pharmaceuticals
